Drug Profile
Evobrutinib - Merck Serono
Alternative Names: M-2951; MSC-2364447; MSC2364447CLatest Information Update: 10 Apr 2024
Price :
$50
*
At a glance
- Originator Merck Serono
- Developer EMD Serono; Merck Serono
- Class Amines; Anti-inflammatories; Antirheumatics; Phenyl ethers; Piperidines; Pyrimidines; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Multiple sclerosis
- No development reported Encephalomyelitis
- Discontinued Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 29 Feb 2024 Pharmacodynamics data from a preclinical trial in multiple sclerosis presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024 (ACTRIMS-2024)
- 05 Dec 2023 Efficacy data from a phase III (EVOLUTION RMS1) trial in Multiple sclerosis released by Merck
- 05 Dec 2023 Efficacy data from a phase III (EVOLUTION RMS2) trial in Multiple sclerosis released by Merck